The serum PSA level of patients with prostate cancer increases compared to those of non-cancer counterparts; however, it is still difficult to discriminate between patients with prostate cancer and those with benign prostate hyperplasia (BPH) when the concentration of PSA is low in sera, which is called a gray zone. The gene discussed is KLK3; the disease is cancer.